Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
  • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
  • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/11—Antisense
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/31—Chemical structure of the backbone
  • C12N2310/315—Phosphorothioates
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/32—Chemical structure of the sugar
  • C12N2310/321—2'-O-R Modification
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/33—Chemical structure of the base
  • C12N2310/334—Modified C
  • C12N2310/3341—5-Methylcytosine
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/30—Chemical structure
  • C12N2310/34—Spatial arrangement of the modifications
  • C12N2310/341—Gapmers, i.e. of the type ===---===

Definitions

• the present disclosure relates to methods for treating hepatitis B virus (HBV) infections. These methods comprise administering to a subject in need thereof an RNA polymerase associated domain containing proteins 5 and 7 (PAPD 5/7) inhibitor and administering a modified antisense oligonucleotide (ASO).
• HBV hepatitis B virus
• Hepatitis B virus is a strict hepatotropic, double-stranded DNA containing virus. Although DNA is the genetic material, the replication cycle involves a reverse transcription step to copy a pregenomic RNA into DNA.
• Primary infection with HBV causes an acute hepatitis with symptoms of organ inflammation, fever jaundice, and increased liver transaminases in blood. Those patients that are not able to overcome the virus infection suffer a chronic disease progression over many years with increased risk of developing cirrhotic liver or liver cancer.
• HBV infection results in the production of two different particles: 1) the HBV virus itself (or Dane particle) which includes a viral capsid assembled from the HBV core antigen protein (HBcAg) and is covered by the hepatitis B surface antigen (HBsAg) and is capable of reinfecting cells and 2) subviral particles (or SVPs) which are high density lipoprotein-like particles comprised of lipids, cholesterol, cholesterol esters and the small and medium forms of the hepatitis B surface antigen (HBsAg) which are non-infectious.
• SVPs subviral particles
• nucleoside and nucleotide therapies entecavir and tenofovir have been successful at reducing viral load, but the rates of HBeAg seroconversion and HBsAg loss are even lower than those obtained using IFNa therapy.
• Other similar therapies including lamivudine (3TC), telbivudine (LdT), and adefovir are also used, but for nucleoside/nucleotide therapies in general, the emergence of resistance limits therapeutic efficacy.
• the present disclosure provides a method for treating a hepatitis B virus (HBV) infection in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A having the structure: or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of a single-stranded modified oligonucleotide including 20 linked nucleosides having a nucleobase sequence of 5'- GCAGAGGTGAAGCGAAGTGC-3' (SEQ ID NO: 1), wherein the modified oligonucleotide includes: a gap segment consisting of ten linked deoxynucleosides, a 5' wing segment consisting of 5 linked nucleosides, and a 3' wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5' wing segment and the 3' wing segment, wherein each nucleoside of each wing segment includes a 2'-O-me
• Compound A described herein is a PAPD5/7 inhibitor, disclosed as Compound No. 220 in WO2019/069293, which is incorporated herein by reference in its entirety.
• the single-stranded modified oligonucleotide described herein is an antisense oligonucleotide (ASO) as disclosed in WO2012/145697, which is incorporated herein by reference in its entirety.
• ASO antisense oligonucleotide
• the ASO is compound ISIS No. 505358 as disclosed in WO2012/145697, and it is also referred to as bepirovirsen.
• the present disclosure provides a method for treating chronic hepatitis B (CHB) in a human in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• CHB chronic hepatitis B
• the present disclosure provides a method for reducing serum HBsAg levels in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of the single-stranded modified oligonucleotide as described herein.
• the present disclosure provides a method for reducing serum HBV DNA levels in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of the single-stranded modified oligonucleotide as described herein.
• a combination for use in the treatment of chronic hepatitis B comprising Compound A having the structure: or a pharmaceutically acceptable salt thereof, and a single-stranded modified oligonucleotide comprising 20 linked nucleosides having a nucleobase sequence of SEQ ID NO:1, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• the combination is for use in a method of treating chronic hepatitis B in a subject, wherein the method comprises administering Compound A and the modified oligonucleotide concomitantly to the subject.
• the combination is for use in a method of treating chronic hepatitis B (CHB) in a human in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• CHB chronic hepatitis B
• the combination is for use in a method of reducing serum HBsAg levels in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of the single-stranded modified oligonucleotide as described herein.
• the combination is for use in a method of reducing serum HBV DNA levels in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A, or a pharmaceutically acceptable salt thereof, and administering to the subject a therapeutically effective amount of the single-stranded modified oligonucleotide as described herein.
• FIG. 1 depicts the structure of chimeric 2'-M0E phosphorothioate oligonucleotides (MOE Gapmer).
• FIG. 2 depicts enzymatic activity of PAPD5 and PAPD7 in biochemical assay for Compound A and RG7834.
• FIG. 3 depicts the effect of monotreatment with Compound A on HBsAg levels in AAV-HBV mice.
• FIG. 4 depicts the effect of concurrent treatment with Compound A and bepirovirsen on HBsAg levels in AAV-HBV mice.
• FIG. 5 depicts the effect of sequential treatment with Compound A and bepirovirsen on HBsAg levels in AAV-HBV mice.
• 2'-O-methoxyethyl refers to an O-methoxy- ethyl modification at the 2' position of a furanose ring.
• a 2'-O-methoxyethyl modified sugar is a modified sugar.
• 2'-O-methoxyethyl nucleoside refers to a nucleoside comprising a 2'-O-methoxyethyl modified sugar moiety.
• 5-methylcytosine refers to a cytosine modified with a methyl group attached to the 5-position.
• a 5-methylcytosine is a modified nucleobase.
• Active pharmaceutical agent refers to the substance or substances in a pharmaceutical composition that provide a therapeutic benefit when administered to a subject.
• an antisense oligonucleotide targeted to HBV is an active pharmaceutical agent.
• a PAPD5/7 inhibitor is an active pharmaceutical agent.
• administering refers to the coadministration of two active pharmaceutical agents to a subject during a time period in any manner in which the first administered active pharmaceutical agent is still present in the subject in a therapeutically effective amount when the second active pharmaceutical agent is administered.
• Concomitant administration does not require that both agents be administered in a single pharmaceutical composition, in the same dosage form, or by the same route of administration. The effects of both agents can be overlapping for a period of time and need not be coextensive.
• administering sequentially refers to administration of a first active pharmaceutical agent, followed by administration of a second active pharmaceutical agent a significant time later such that the first administered active pharmaceutical agent is not present in the subject in a therapeutically effective amount when the second active pharmaceutical agent is administered.
• the period of time between two sequential administrations may be between 1 week and 24 weeks, for example, between 2 weeks and 12 weeks, for example, 1 week, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, or 12 weeks.
• Animal refers to a human or non-human animal, including, but not limited to, mice, rats, rabbits, dogs, cats, pigs, and non-human primates, including, but not limited to, monkeys and chimpanzees.
• Antisense compound refers to an oligomeric compound that is capable of undergoing hybridization to a target nucleic acid through hydrogen bonding.
• antisense compounds include single-stranded and double-stranded compounds, such as, antisense oligonucleotides, siRNAs, shRNAs, snoRNAs, miRNAs, and satellite repeats.
• Antisense oligonucleotide refers to a single-stranded oligonucleotide having a nucleobase sequence that permits hybridization to a corresponding region or segment of a target nucleic acid.
• “Chemically distinct region” refers to a region of an antisense compound that is in some way chemically different than another region of the same antisense compound. For example, a region having 2'-O-methoxyethyl nucleos(t)ides is chemically distinct from a region having nucleos(t)ides without 2'-O-methoxy ethyl modifications.
• Chimeric antisense compound refers to an antisense compound that has at least 2 chemically distinct regions, each region having a plurality of subunits.
• CHB infection occurs when a person initially suffers from an acute infection but is then unable to fight off the infection. About 90% of infants infected at birth will progress to chronic disease. However, as a person ages, the risk of chronic infection decreases such that between 20%-50% of people infected as children and less than 10% of people infected as adults will progress from acute to chronic infection.
• Deoxyribonucleoside refers to a nucleoside having a hydrogen at the 2' position of the sugar portion of the nucleoside. Deoxyribonucleosides may be modified with any of a variety of substituents.
• Dose refers to a specified quantity of a pharmaceutical agent provided in a single administration, or in a specified time period.
• a dose may be administered in two or more boluses, tablets, or injections.
• the desired dose requires a volume not easily accommodated by a single injection.
• two or more injections may be used to achieve the desired dose.
• a dose may be administered in two or more injections to minimize injection site reaction in an individual.
• Dosing regimen is a combination of doses designed to achieve one or more desired effects.
• Duration refers to the period of time during which an activity or event continues.
• the duration of treatment is the period of time during which doses of a pharmaceutical agent are administered.
• “Effective amount” in the context of modulating an activity or of treating or preventing a condition refers to the administration of that amount of an active ingredient to a subject in need of such modulation, treatment, or prophylaxis, either in a single dose or as part of a series, that is effective for modulation of that effect, or for treatment or prophylaxis or improvement of that condition.
• “Gapmer” refers to a chimeric antisense compound in which an internal region having a plurality of nucleosides that support RNase H cleavage is positioned between external regions, wherein the nucleosides comprising the internal region are chemically distinct from the nucleosides comprising the external regions.
• the internal region may be referred to as the “gap,” “gap region,” or “gap segment,” and the external regions may be referred to as the “wings,” “wing regions,” or “wing segments.”
• HBV refers to mammalian hepatitis B virus, including human hepatitis B virus.
• the term encompasses geographical genotypes of hepatitis B virus, particularly human hepatitis B virus, as well as variant strains of geographical genotypes of hepatitis B virus.
• Human geographical genotypes of HBV include genotypes: A (Northwest Europe, North America, Central America); B (Indonesia, China, Vietnam); C (East Asia, Korea, China, Japan, Polynesia, Vietnam); D (Mediterranean area, Middle East, India); E (Africa); F (Native Americans, Polynesia); G (United States, France); and H (Central America).
• HBV antigen refers to any hepatitis B virus antigen or protein, including core proteins such as “hepatitis B core antigen” or “HBcAg,” “hepatitis B E antigen” or “HBeAg,” and envelope proteins such as “HBV surface antigen” or “HBsAg.”
• Hepatitis B E antigen or “HBeAg” is a secreted, non-particulate form of HBV core protein.
• HBV antigens HBeAg and HBeAg share primary amino acid sequences, so show crossreactivity at the T cell level.
• HBeAg is not required for viral assembly or replication, although studies suggest it may be required for establishment of chronic infection.
• HBV surface antigen or “HBsAg” is the envelope protein of infectious HBV viral particles (Dane particles) but is also secreted as a non-infectious subviral particle (SVP) with serum levels 1000-fold higher than HBV viral particles.
• SVP non-infectious subviral particle
• the serum levels of HBsAg in an infected person or animal can be as high as 1000 pg/mL (Kann and Gehrlich (1998) Topley & Wilson’s Microbiology and Microbial Infections, 9th ed. 745).
• Hepatitis B-related condition or “HBV-related condition” refers to any disease, biological condition, medical condition, or event which is exacerbated, caused by, related to, associated with, or traceable to a hepatitis B infection, exposure, or illness.
• hepatitis B- related condition includes chronic HBV infection, inflammation, fibrosis, cirrhosis, liver cancer, serum hepatitis, jaundice, liver inflammation, liver fibrosis, liver failure, diffuse hepatocellular inflammatory disease, hemophagocytic syndrome, HBV viremia, liver disease related to transplantation, and conditions having symptoms which may include any or all of the following: flu-like illness, weakness, aches, headache, fever, loss of appetite, diarrhea, nausea and vomiting, pain over the liver area of the body, clay- or grey-colored stool, itching all over, and dark-colored urine, when coupled with a positive test for presence of a hepatitis B virus, a hepatitis B viral antigen, or a positive test for the presence of an antibody specific for a hepatitis B viral antigen.
• “Induce,” “inhibit,” “potentiate,” “elevate,” “increase,” “decrease” or the like generally denote quantitative differences between two states. Such terms may refer to a statistically significant difference between the two states.
• an amount effective to inhibit the activity or expression of HBV refers to the level of activity or expression of HBV in a treated cell that is quantitatively different, and may be statistically significant, from the level of HBV activity or expression in untreated cells. Such terms are applied to, for example, levels of expression, and levels of activity.
• Internucleoside linkage refers to the chemical bond between nucleosides.
• Phosphodiester and phosphorothioate are examples of internucleoside linkages.
• Linked nucleosides refers to adjacent nucleosides linked together by an internucleoside linkage.
• Modified internucleoside linkage refers to a substitution or any change from a naturally occurring internucleoside bond (i.e., a phosphodi ester internucleoside bond), for example a phosphorothioate internucleoside bond.
• Modified nucleobase refers to any nucleobase other than adenine, cytosine, guanine, thymidine, or uracil.
• An “unmodified nucleobase” refers to the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
• a modified nucleobase includes methyl-cytosine.
• Modified nucleoside refers to a nucleoside having, independently, a modified sugar moiety and/or modified nucleobase.
• Modified nucleotide refers to a nucleotide having, independently, a modified sugar moiety, modified internucleoside linkage, and/or modified nucleobase.
• Modified oligonucleotide refers to an oligonucleotide comprising at least one modified internucleoside linkage, a modified sugar, and/or a modified nucleobase.
• a modified oligonucleotide may be, according to some embodiments of the present disclosure, a chimeric antisense compound including an internal region having a plurality of nucleosides that support RNase H cleavage, positioned between external regions, for example, between two external regions, such as a 5' external region and a 3' external region, each external region having one or more nucleosides, and wherein the nucleosides included in the internal region are chemically distinct from the nucleosides included in the external regions.
• a modified oligonucleotide can be in the form of a free acid or a pharmaceutically acceptable salt thereof (e.g. a sodium salt), or a mixture thereof.
• Nucleic acid refers to molecules composed of monomeric nucleotides.
• a nucleic acid includes, but is not limited to, ribonucleic acids (RNA), deoxyribonucleic acids (DNA), singlestranded nucleic acids, double-stranded nucleic acids, small interfering ribonucleic acids (siRNA), and microRNAs (miRNA).
• Nucleic acids may include modified and/or unmodified nucleotides without limitation.
• Nucleobase refers to a heterocyclic moiety capable of pairing with a base of another nucleic acid.
• Nucleobase sequence refers to the order of contiguous nucleobases independent of any sugar, linkage, and/or nucleobase modification.
• Oligonucleotide refers to a polymer of linked nucleosides, each of which can be modified or unmodified, independent one from another.
• “Pharmaceutically acceptable salts” refer to physiologically and pharmaceutically acceptable salts of compounds, i.e., salts that retain the desired biological activity of the parent active ingredients and do not impart undesired toxicological effects thereto.
• “Pharmaceutical agent” refers to a substance that provides a therapeutic benefit when administered to a subject.
• a PAPD5/7 inhibitor, and/or an antisense oligonucleotide targeting HBV RNA are pharmaceutical agents.
• Phosphorothioate linkage refers to a linkage between nucleosides where the phosphodiester bond is modified by replacing one of the non-bridging oxygen atoms with a sulfur atom.
• a phosphorothioate linkage is a modified internucleoside linkage.
• Region is defined as a portion of, for example, a nucleic acid having at least one identifiable structure, function, or characteristic.
• “Segments” may refer to smaller, or sub-portions of, regions within, for example, a nucleic acid.
• “Seroclearance” refers to HBsAg and/or HBV DNA levels below the lower limit of quantification (i.e. ⁇ LLOQ) in a CHB patient.
• the LLOQ is 0.05 lU/mL.
• the LLOQ is 20 lU/mL.
• Subject refers to a human or non-human animal selected for treatment or therapy. In one embodiment, the subject is a human.
• “Therapeutically effective amount” refers to the administration of an agent to a subject, either alone or as part of a pharmaceutical composition and either in a single dose or as part of a series of doses, in an amount capable of having any detectable, positive effect on any symptom, aspect, or characteristic of a disease or condition when administered to the subject.
• Treatment refers to administering a composition to a subject to affect an alteration or improvement of the disease or condition.
• treating as used herein in relation to chronic hepatitis B infection refers to the administration of suitable compositions with the intention of reducing the symptoms of CHB, preventing the progression of CHB or reducing the level of one or more detectable markers of CHB.
• the present disclosure provides methods for treating a hepatitis B virus (HBV) infection.
• HBV infection is chronic hepatitis B (CHB).
• the methods for treating an HBV infection in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a PAPD5/7 inhibitor and an antisense oligonucleotide.
• the method for treating an HBV infection in a subject in need thereof comprises administering to the subject a therapeutically effective amount of Compound A having the structure:
• the method comprises administering to the subject a therapeutically effective amount of Compound A and administering to the subject a singlestranded modified oligonucleotide comprising 20 linked nucleosides and having a nucleobase sequence:
• the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• Compound A is administered as a free acid. In another embodiment, Compound A is administered as a pharmaceutically acceptable salt thereof.
• the modified oligonucleotide consists of 20 linked nucleosides and having a nucleobase sequence of SEQ ID NO: 1.
• the modified oligonucleotide is bepirovirsen.
• bepirovirsen is administered as a free acid, a pharmaceutically acceptable salt thereof (e.g., a sodium salt), or a combination thereof.
• bepirovirsen is administered as a free acid.
• bepirovirsen is administered as a pharmaceutically acceptable salt thereof (e.g., a sodium salt).
• bepirovirsen is administered as a combination of a free acid and a sodium salt.
• the methods for treating an HBV infection in a subject in need thereof comprises administering to the subject a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• the therapeutically effective amount of bepirovirsen is calculated based on the amount of bepirovirsen free acid.
• the subject may be a human.
• the present disclosure provides a method for treating chronic hepatitis B (CHB) in a human in need thereof, the method comprising administering to the subject a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• CHB chronic hepatitis B
• the subject is on stable nucleos(t)ide analogue (NA) therapy (e.g., tenofovir disoproxil, tenofovir alafenamide, or entecavir).
• NA nucleos(t)ide analogue
• “Stable” is defined as no changes to the nucleos(t)ide regimen for at least 6 months prior to the treatment and with no planned changes to the regimen for the duration of the treatment.
• the NA therapy is lamivudine, adefovir, adefovir dipivoxil, telbivudine, entecavir, tenofovir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF), or a pharmaceutically acceptable salt thereof.
• the NA therapy is entecavir, tenofovir, tenofovir disoproxil fumarate, or tenofovir alafenamide.
• the NA therapy is entecavir.
• the NA therapy is tenofovir.
• the NA therapy is tenofovir disoproxil fumarate.
• the NA therapy is tenofovir alafenamide.
• the subject is not on NA therapy. In some embodiments, the subject is treatment-naive.
• Compound A is administered orally. In one embodiment, Compound A is administered as a capsule. In one embodiment, Compound A is administered as a tablet. In some embodiments, Compound A is administered to a subject under fasted conditions. In some embodiments, Compound A is administered to a subject under fed conditions. In some embodiments, Compound A is administered for 1 week, 2 weeks, 3 weeks, or 4 weeks. In some embodiments, Compound A is administered for 4 weeks, 8 weeks, or 12 weeks. In one embodiment, Compound A is administered for 4 weeks.
• the modified oligonucleotide is administered by subcutaneous injection. In some embodiments, the modified oligonucleotide is administered by subcutaneous injection in an aqueous solution. In some embodiments, the modified oligonucleotide is administered at a dose of about 150 mg or 300 mg once weekly. In one embodiment, the modified oligonucleotide is administered at a dose of about 150 mg once weekly. In another embodiment, the modified oligonucleotide is administered at a dose of about 300 mg once weekly. In some embodiments, the modified oligonucleotide is administered weekly with additional loading doses in the first two weeks on Day 4 and Day 11. In another embodiment, the modified oligonucleotide is administered at a dose of about 300 mg once weekly, with additional loading doses on Day 4 and Day 11.
• the modified oligonucleotide is administered for about 12-24 weeks. In some embodiments, the modified oligonucleotide is administered for 12 weeks, 14 weeks, 16 weeks, 18 weeks, 20 weeks, 22 weeks, or 24 weeks. In one embodiment, the modified oligonucleotide is administered for 12 weeks. In one embodiment, the modified oligonucleotide is administered for 24 weeks. In one embodiment, the modified oligonucleotide is bepirovirsen and is administered for 12 weeks or 24 weeks, with additional loading doses on Day 4 and Day 11.
• Compound A and the modified oligonucleotide are administered concomitantly. In some embodiments, Compound A and the modified oligonucleotide are administered concomitantly for a first treatment period. In some embodiments, the first treatment period is 2 to 12 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, or 12 weeks. In some embodiments, the first treatment period is 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks. In some embodiments, the first treatment period is 4 to 12 weeks. In one embodiment, Compound A and bepirovirsen are administered concomitantly for a first treatment period (e.g. 4 weeks, 8 weeks, or 12 weeks). In one embodiment, Compound A and bepirovirsen are administered concomitantly for 4 weeks. In one embodiment, Compound A and bepirovirsen are administered concomitantly for
• Compound A and bepirovirsen are administered concomitantly for 12 weeks.
• the modified oligonucleotide is administered alone for a second treatment period.
• the second treatment period is 8 to 20 weeks. In some embodiments, the second treatment period is 8 to 48 weeks. In some embodiments, the second treatment period is 8 weeks,
• the second treatment period is 8 weeks. In one embodiment, the second treatment period is 20 weeks.
• Compound A is administered alone for a second treatment period.
• the second treatment period is 4 to 12 weeks. In some embodiments, the second treatment period is 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks.
• Compound A and the modified oligonucleotide are administered concomitantly for a first treatment period, and then the modified oligonucleotide is administered alone for a second treatment period.
• the first treatment period is 4 weeks and the second treatment period is 8 to 20 weeks.
• Compound A and bepirovirsen are administered concomitantly for 4 weeks and then bepirovirsen is administered alone for 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, or 20 weeks.
• Compound A and bepirovirsen are administered concomitantly for 4 weeks and then bepirovirsen is administered alone for 8 weeks. In one embodiment, Compound A and bepirovirsen are administered concomitantly for 4 weeks and then bepirovirsen is administered alone for 20 weeks.
• Compound A and the modified oligonucleotide are administered concomitantly for a first treatment period, and then Compound A is administered alone for a second treatment period.
• the first treatment period is 12 weeks and the second treatment period is 4 to 12 weeks.
• Compound A and bepirovirsen are administered concomitantly for 12 weeks and then Compound A is administered alone for 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks.
• the present disclosure provides that the amount of Compound A and/or the singlestranded oligonucleotide administered to a subject as set forth herein is a therapeutically effective amount.
• Compound A is administered twice a day. In some embodiments, the amount of Compound A administered is between about 0.02-20 mg per dose, or about 0.02 mg, 0.05 mg, 0.1 mg, 0.3 mg, 0.5 mg, 1 mg, 3 mg, 10 mg, or 20 mg per dose, or in a range between any two of the preceding values (e.g.
• Compound A is administered at about 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg per dose, or in a range between any two of the preceding values, for example, about 0.5-1 mg, about 0.5-2 mg, about 1- 10 mg, about 2-6 mg, or about 3-5 mg per dose. In some embodiments, Compound A is administered at about 0.5 mg, 1 mg, 3 mg, or 10 mg per dose. In some embodiments, Compound A is administered at about 0.5 mg per dose. In some embodiments, Compound A is administered at about 1 mg per dose. In some embodiments, Compound A is administered at about 3 mg per dose.
• Compound A is administered at a dose of about 1 to 10 mg or about 1 to 20 mg twice a day. In some embodiments, Compound A is administered at a dose of about 3 mg twice a day. In some embodiments, Compound A is administered at a dose of about 0.5 mg or about 1 mg twice a day. In some embodiments, Compound A is administered at a dose of about 0.5 mg twice a day. In some embodiments, Compound A is administered at a dose of about 1 mg twice a day.
• administering decreases HBV RNA levels, HBV DNA levels, HBV protein levels, HBsAg levels, or HBeAg levels in the blood by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%.
• administration of Compound A and bepirovirsen decreases serum HBV DNA levels and/or serum HBsAg levels by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 99%.
• the hepatitis B virus infection is caused by any of the human geographical genotypes: A (Northwest Europe, North America, Central America); B (Indonesia, China, Vietnam); C (East Asia, Korea, China, Japan, Polynesia, Vietnam); D (Mediterranean area, Middle East, India); E (Africa); F (Native Americans, Polynesia); G (United States, France); or H (Central America).
• the subject has chronic hepatitis B (CHB).
• the subject achieves seroclearance of hepatitis B surface antigen (HBsAg) at the end of the treatment. In some embodiments, the subject maintains seroclearance of HBsAg 24 weeks after the end of the treatment. “The end of the treatment” refers to administration of the final dose of Compound A or the final dose of the modified oligonucleotide for the methods described herein, whichever is later. [00094] In some embodiments, the subject achieves seroclearance of HBV DNA at the end of the treatment. In some embodiments, the subject maintains seroclearance of HBV DNA 24 weeks after the end of the treatment.
• HBsAg hepatitis B surface antigen
• the subject achieves seroclearance of HBsAg at the end of the treatment. In some embodiments, the subject maintains seroclearance of HBsAg 24 weeks after the end of the treatment.
• the subject achieves seroclearance of HBsAg and HBV DNA at the end of the treatment. In some embodiments, the subject maintains seroclearance of HBsAg and HBV DNA 24 weeks after the end of the treatment.
• the methods described herein provide a higher response rate for the subjects receiving the combination therapy (Compound A and bepirovirsen) to achieve seroclearance of HBV DNA at the end of the treatment or 24 weeks after the end of the treatment, as compared to those receiving a monotherapy (Compound A or bepirovirsen).
• the response rate for the subjects receiving the combination therapy is at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% higher than those receiving a monotherapy.
• the methods described herein also provide a higher response rate for the subjects receiving the combination therapy (Compound A and bepirovirsen) to achieve seroclearance of HBsAg at the end of the treatment or 24 weeks after the end of the treatment, as compared to those receiving a monotherapy (Compound A or bepirovirsen).
• the response rate for the subjects receiving the combination therapy is at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% higher than those receiving a monotherapy.
• the methods described herein further provide a higher response rate for the subjects receiving the combination therapy (Compound A and bepirovirsen) to achieve seroclearance of HBsAg and HBV DNA at the end of the treatment or 24 weeks after the end of the treatment, as compared to those receiving a monotherapy (Compound A or bepirovirsen).
• the response rate for the subjects receiving the combination therapy is at least 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, or 15% higher than those receiving a monotherapy.
• the subject achieves a reduction of at least 1, at least 1.5, at least 2, at least 2.5, or at least 3 loglO lU/mL in HBsAg levels from baseline at the end of the treatment. In some embodiments, the subject maintains a reduction of at least 1, at least 1.5, at least 2, at least 2.5, or at least 3 loglO lU/mL in HBsAg levels from baseline 24 weeks after the end of the treatment.
• the present disclosure provides a combination for use in the treatment of an HBV infection, comprising Compound A having the structure: a single-stranded modified oligonucleotide comprising 20 linked nucleosides and having a nucleobase sequence of SEQ ID NO:1, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• Compound A having the structure: a single-stranded modified oligonucleo
• the present disclosure relates to use of Compound A in the manufacture of a medicament for the treatment of an HBV infection, wherein Compound A is to be administered with a single-stranded modified oligonucleotide comprising 20 linked nucleosides and having a nucleobase sequence of SEQ ID NO: 1, wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• the present disclosure relates to use of a single-stranded modified oligonucleotide in the manufacture of a medicament for the treatment of an HBV infection, wherein the modified oligonucleotide comprises 20 linked nucleosides and has a nucleobase sequence of SEQ ID NO:1, and comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• the present disclosure relates to use of a combination of Compound A and a single-stranded modified oligonucleotide in the manufacture of a medicament for the treatment of an HBV infection, wherein the modified oligonucleotide comprises 20 linked nucleosides and has a nucleobase sequence of SEQ ID NO:1, and comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• the modified oligonucleotide comprises 20 linked nucleo
• the combination of Compound A and the modified oligonucleotide is for use in the treatment of chronic hepatitis B (CHB) in a human in need thereof.
• CHB chronic hepatitis B
• the combination of Compound A and the modified oligonucleotide is for use in the manufacture of a medicament for the treatment of CHB in a human in need thereof.
• modified oligonucleotide e.g. bepirovirsen
• Doses and dosage intervals recited above in relation to methods of the invention are also appropriate for medical uses of the invention.
• the present disclosure also provides pharmaceutical combinations for treating a hepatitis B virus (HBV) infection.
• HBV infection is chronic hepatitis B (CHB).
• CHB chronic hepatitis B
• the combinations disclosed herein may be used in any of the preceding methods.
• the combination comprises two compositions: a first composition comprising a first pharmaceutical component, and a second composition comprising a second pharmaceutical component.
• the first composition comprises a PAPD5/7 inhibitor such as Compound A
• the second composition comprises an antisense oligonucleotide such as bepirovirsen.
• the combination comprises a PAPD5/7 inhibitor and an antisense oligonucleotide.
• the combination comprises a first composition comprising a PAPD5/7 inhibitor, and a second composition comprising an antisense oligonucleotide.
• the combination may be for use in the treatment of an HBV infection in a subject in need thereof, wherein the treatment comprises administering to the subject a therapeutically effective amount of a PAPD5/7 inhibitor and an antisense oligonucleotide.
• the combination comprises Compound A having the structure: or a pharmaceutically acceptable salt thereof.
• the combination comprises Compound A and a single-stranded modified oligonucleotide comprising 20 linked nucleosides having the nucleobase sequence: 5'-GCAGAGGTGAAGCGAAGTGC-3' (SEQ ID NO: 1), wherein the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynucleosides, a 5’ wing segment consisting of 5 linked nucleosides, and a 3’ wing segment consisting of 5 linked nucleosides, wherein the gap segment is positioned between the 5’ wing segment and the 3’ wing segment, wherein each nucleoside of each wing segment comprises a 2’-O-methoxyethyl sugar, wherein each internucleoside linkage is a phosphorothioate linkage, and wherein each cytosine is a 5- methylcytosine.
• the modified oligonucleotide comprises: a gap segment consisting of ten linked deoxynu
• Compound A is a free acid. In another embodiment, Compound A is a pharmaceutically acceptable salt thereof.
• the modified oligonucleotide consists of 20 linked nucleosides having a nucleobase sequence of SEQ ID NO: 1.
• the modified oligonucleotide is bepirovirsen.
• bepirovirsen is administered as a free acid, a pharmaceutically acceptable salt thereof (e.g., a sodium salt), or a combination thereof.
• bepirovirsen is administered as a free acid.
• bepirovirsen is administered as a pharmaceutically acceptable salt thereof (e.g., a sodium salt).
• bepirovirsen is administered as a combination of a free acid and a sodium salt.
• the combination is for use in a method of treating an HBV infection in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• the present disclosure provides a combination for use in a method of treating chronic hepatitis B (CHB) in a human in need thereof, the method comprising administering to the human a therapeutically effective amount of Compound A and a therapeutically effective amount of bepirovirsen.
• CHB chronic hepatitis B
• the subject is on stable nucleos(t)ide analogue (NA) therapy (e.g., tenofovir disoproxil, tenofovir alafenamide, or entecavir).
• NA nucleos(t)ide analogue
• the NA therapy is lamivudine, adefovir, adefovir dipivoxil, telbivudine, entecavir, tenofovir, tenofovir disoproxil fumarate (TDF), or tenofovir alafenamide (TAF), or a pharmaceutically acceptable salt thereof.
• the NA therapy is entecavir, tenofovir, tenofovir disoproxil fumarate, or tenofovir alafenamide. In some embodiments, the NA therapy is entecavir. In some embodiments, the NA therapy is tenofovir. In some embodiments, the NA therapy is tenofovir disoproxil fumarate. In some embodiments, the NA therapy is tenofovir alafenamide.
• the subject is not on NA therapy prior to administration of Compound A or the modified oligonucleotide. In some embodiments, the subject is treatment- naive.
• Compound A is for oral administration. In one embodiment, Compound A is formulated as a capsule. In one embodiment, Compound A is formulated as a tablet.
• the modified oligonucleotide is formulated for delivery by subcutaneous injection. In some embodiments, the modified oligonucleotide is in an aqueous solution. In some embodiments, the combination comprises 150 mg or 300 mg of the modified oligonucleotide.
• the combination is for use in a method wherein Compound A and the modified oligonucleotide are administered concomitantly.
• this concomitant administration takes place for a first treatment period.
• the first treatment period is 2 to 12 weeks, for example, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11, weeks, or 12 weeks.
• the first treatment period is 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, or 12 weeks. In one embodiment, the first treatment period is 4 weeks.
• the combination comprises Compound A and bepirovirsen for use in a method wherein they are administered concomitantly for a first treatment period (e.g. 4 weeks, 8 weeks, or 12 weeks). In one embodiment, the combination comprises Compound A and bepirovirsen for use in a method wherein they are administered concomitantly for 4 weeks.
• the present disclosure provides a combination comprising therapeutically effective amounts of Compound A and the single-stranded oligonucleotide.
• the combination comprises 0.02-20 mg of Compound A, or 0.02 mg, 0.05 mg, 0.1 mg, 0.3 mg, 0.5 mg, 1 mg, 3 mg, 10 mg, or 20 mg of Compound A, or an amount in a range between any two of the preceding values (e.g.
• the combination comprises 0.5 mg, 1 mg, 2 mg, 3 1 mg, 4 mg, 5 mg, 6 mg, 7 mg, 8 mg, 9 mg, or 10 mg of Compound A, or an amount between any two of the preceding values, for example, about 0.5-1 mg, 1-10 mg, 2-6 mg, or about 3-5 mg.
• the combination comprises 0.5 mg, 1 mg, 3 mg, or 10 mg of Compound A.
• the combination comprises 3 mg of Compound A.
• the combination comprises 0.5 mg of Compound A.
• the combination comprises 1 mg of Compound A.
• the combination comprises 150 mg of the modified oligonucleotide and 3 mg of Compound A. In another embodiment, the combination comprises 300 mg of the modified oligonucleotide and 3 mg of Compound A. In one embodiment, the combination comprises 150 mg of the modified oligonucleotide and 0.5-1 mg of Compound A. In another embodiment, the combination comprises 300 mg of the modified oligonucleotide and 0.5- 1 mg of Compound A. In one embodiment, the combination comprises 150 mg of the modified oligonucleotide and 0.5 mg of Compound A. In another embodiment, the combination comprises 300 mg of the modified oligonucleotide and 0.5 mg of Compound A. In one embodiment, the combination comprises 150 mg of the modified oligonucleotide and 1 mg of Compound A. In another embodiment, the combination comprises 300 mg of the modified oligonucleotide and 1 mg of Compound A. In another embodiment, the combination comprises 300 mg of the modified oligonucleotide and 1 mg of Compound A
• the active pharmaceutical agents disclosed herein in particular in the form of pharmaceutical compositions, are included in a kit with instructions for use.
• the kit comprises an antisense oligonucleotide targeted to HBV, i.e., the modified oligonucleotide as disclosed herein, and a PAPD5/7 inhibitor, as disclosed herein, in separate containers.
• the kit comprises bepirovirsen.
• the kit comprises Compound A or a pharmaceutically acceptable salt thereof.
• the kit comprises bepirovirsen. and Compound A or a pharmaceutically acceptable salt thereof.
• the kit may comprise the active pharmaceutical agents in predetermined amounts with instructions for use. In an embodiment, the predetermined amounts are as disclosed in the Combinations section above. In an embodiment, the kit comprises the 300 mg of modified oligonucleotide. In an embodiment, the kit comprises 150 mg of modified oligonucleotide. [000126] In an embodiment, the kit comprises Compound A formulated for oral administration. In an embodiment, the kit comprises one or more capsules or tablets comprising Compound A. In an embodiment, the kit comprises one or more capsules or tablets comprising 0.02-20 mg of Compound A. In an embodiment, each capsule or tablet comprises 0.5-1 mg of compound A. In an embodiment, each capsule or tablet comprises 0.5 mg of Compound A. In an embodiment, each capsule or tablet comprises 1 mg of Compound A. In an embodiment, Compound A is formulated as a tablet. In an embodiment, Compound A is formulated in a capsule.
• the kit may also include a device to be used for administration of a pharmaceutical composition.
• the kit comprises other medicaments.
• the potency (pICso) of Compound A for reduction of HBV HBsAg was investigated in primary human hepatocytes (PHH) from three donors. HBV infected PHH samples were treated with Compound A for 21 days and secreted HBsAg was measured using an ELISA assay to determine the % inhibition and average potency of the replicates (two per PHH donor). Compound A showed a similar potency in HBsAg reduction across the three different PHH donors with an average pIC50 of 9.08. Visual examination showed no detected sign of cell toxicity.
• HepAD38 cells were maintained in collagen-coated flasks in cell culture medium (DMEM/F12 containing 10% fetal bovine serum (FBS), GlutaMax-1, penicillin/streptomycin, non-essential amino acids, Na pyruvate, 250 pg/mL geneticin, and 1 pg/mL doxycycline).
• Compound solutions were prepared in DMSO and compounds were serially diluted for final concentrations of 4000, 1000, 250, 62.5, 15.6, 3.91, 0.977, 0.244, 0.061, and 0.015 nM. The cells were then trypsinized and the cells were plated at 10,000 cells per well. Plates were incubated at 37°C, 5% CO2 for 4 days.
• Example 4 Comparison of Biochemical Enzyme Inhibition of PAPD5/7 Inhibitors [000133] Dose-response studies were conducted for Compound A and RG7834 in the PAPD5 and PAPD7 Al 5 RNA SPA formats. Four different batches of Compound A and two different batches of RG7834 were used in both assays. Reactions contained 5 uM ATP, 0.0025 uCi/uL 3H- ATP, 50 nM A15 RNA, 10 nM enzyme in assay buffer (20 mM Tris 7.5, 3 mM CHAPS, 0.05% dBSA, 10 mM MgCh, 1 mM DTT, 25 mM KC1).
• Reaction product was detected using SPA bead mix, final concentrations were 1 mg/mL PEI-PS, 1.25 mM ATP, 11.25 mM EDTA. End point signal detection correlated with slopes of reaction time courses. Curve fitting was performed using 4-parameter fitting in ActivityBase software. Compound A average pIC50 values in the PAPD5 and PAPD7 assays were 7.9 and 7.7, respectively. The data shows that Compound A was more potent than RG7834 by >0.5 log (see FIG. 2).
• HBeAg HBeAg was reduced by 0.15 to 0.44 log in the Compound A 3 or 30 mg/kg + bepirovirsen 20 or 40 mg/kg dose groups. Rebound of HBeAg in these combination groups occurred similarly to the mono-therapy dose groups for bepirovirsen.
• HBV DNA There was a strong reduction in HBV DNA of more than 2.5 log in all bepirovirsen dose groups (with or without Compound A) that stabilized by day 14 of treatment.
• HBV DNA remained reduced by 0.84 to 1.35 log for groups receiving 20 mg/kg bepirovirsen and by 1.72 to 2.01 log for groups receiving 40 mg/kg bepirovirsen when compared to the combined vehicle group. All treatments were well tolerated based on body weight profiles.
• PBPK physiologically based PK
• ACAT advanced compartmental absorption and transit
• Values are the protein binding adjusted human total concentrations.
• the minimum therapeutic dose is defined as the dose that provides a Cmin at steady state associated with activity more than the 90% of predicted maximal pharmacologic activity (Cmin >IC90).
• the maximum single dose is defined based on the following:
• Example 7 A 4-part, randomized, double-blind, multi-center, placebo-controlled study to assess the safety, tolerability, PK, and PD of Compound A monotherapy in healthy participants and in CHB patients; and Compound A in combination with bepirovirsen in CHB patients [000148]
• the first two parts of this study will evaluate the safety, tolerability, and pharmacokinetics (PK) of single (Part 1) and repeat doses (Part 2A) of Compound A, and tablet/food effect with single dose (Part 2B) in healthy participants.
• Part 3 will evaluate the ability of Compound A to lower HBsAg in participants living with chronic hepatitis B infection (PLWCHB).
• Part 4 will evaluate the safety and tolerability of combination therapy with Compound A and bepirovirsen and the potential to effect sustained virologic response in PLWCHB.
• Part 4 is a 12- week, repeat dose single dose level study of Compound A in combination with bepirovirsen in PLWCHB on stable NA therapy who have not participated in Part 3 of the study. Sixty participants will be randomized in a 3:1 ratio (45 participants on active and 15 participants on placebo) to receive either Compound A or placebo as oral tablets twice daily (approximately 12h dosing intervals) for 28 days. The dose of Compound is to be determined based on the results from Parts 1-3 of this study. In addition, all participants in this cohort will also receive open label bepirovirsen (300 mg subcutaneous [SC], weekly, plus loading dose on Day 4 and Day 11) concomitantly for 28 days. Bepirovirsen dosing will continue for additional 8 weeks after Compound A dosing completes (for a total of 12 weeks). The patients will be monitored in follow-up for 24 weeks after last bepirovirsen dose.
• the primary efficacy endpoint is sustained virologic response, which is a composite endpoint defined as HBsAg ⁇ LLOQ (0.05 lU/mL) and HBV DNA ⁇ LLOQ (20 lU/mL) at the end of bepirovirsen treatment which is sustained for 24 weeks post-bepirovirsen treatment.
• Serum HBsAg level is measured by a sandwich immunoassay with COBAS HBsAg quant II (Roche).
• Serum HBV DNA level is measure with COBAS Ampliprep/COBAS Taqman HBV test v.2.0 (Roche).
• Seroclearance in this trial refers to participants with HBsAg and HBV DNA ⁇ LLOQ (with or without the formation of HBs-antibody). Seroconversion refers to participants with HBsAg and HBV DNA ⁇ LLOQ plus formation of HBs-antibody. Both terms are used to evaluate efficacy.
• sustained response is defined as a continuous 24 weeks from end of bepirovirsen treatment during which levels of HBsAg in serum remain less than LLOQ and HBV DNA less than LLOQ.
• HBV-infected primary human hepatocytes PHH are allowed 3 days post plating in collagen coated 96- well plates to establish monolayers and assimilate to in vitro culture, followed by HBV infection at an MOI of 200 - 500 genome equivalents (GE)/cell.
• HBV infected (or noninfected control) PHH are treated 7 days after HBV infection, and treatment continues at a predetermined dosing frequency until study termination on Day 21 post treatment / Day 28 post infection.
• Dosing is performed in a checkerboard matrix layout in which 8 serial dilutions of bepirovirsen and 8 serial dilutions of Compound A are combined.
• the highest evaluated concentration of each treatment is serially diluted 3, 4, of 5 -fold to include concentrations expected to result in 0 and maximal % inhibition.
• the serial dilution scheme positions the EC50 of each treatment, determined in prior in vitro studies of HBV-infected PHH, near the center of the expected dose response curve.
• monotherapy is investigated as a comparator when combined with vehicle control. Each treatment within a single 96-well plate is tested in singleton; however, each plate is run in replicates of 2-3 to assess assay and biological variability.
• culture supernatant is collected and stored until analysis at -80 °C.
• Levels of secreted HBsAg in culture supernatant serve as the primary efficacy readout of bepirovirsen and Compound A activity. Additional viral endpoints may be assessed to determine the antiviral effect of combining bepirovirsen and Compound A on production of other HBV antigens, HBV RNA, and HBV DNA.
• Statistical analysis is performed using synergy software to determine whether a synergistic, antagonistic or other effect is observed when bepirovirsen and Compound A are combined.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Virology (AREA)
• Epidemiology (AREA)
• Biotechnology (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Biomedical Technology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Biophysics (AREA)
• Plant Pathology (AREA)
• Microbiology (AREA)
• Physics & Mathematics (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=85172882

Family Applications (1)

Country Status (8)

Cited By (2)

Citations (4)

• 2023
  • 2023-01-26 US US18/832,756 patent/US20250092401A1/en active Pending
  • 2023-01-26 CA CA3243401A patent/CA3243401A1/en active Pending
  • 2023-01-26 CN CN202380019294.XA patent/CN118660704A/zh active Pending
  • 2023-01-26 WO PCT/IB2023/050687 patent/WO2023144750A1/en not_active Ceased
  • 2023-01-26 EP EP23703336.0A patent/EP4469161A1/en active Pending
  • 2023-01-26 KR KR1020247028356A patent/KR20240144245A/ko active Pending
  • 2023-01-26 AU AU2023213173A patent/AU2023213173B2/en active Active
  • 2023-01-26 JP JP2024544889A patent/JP2025504017A/ja active Pending

Patent Citations (4)

Non-Patent Citations (5)

Also Published As

Similar Documents

Legal Events